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Backgrounds: Neutrophil-lymphocyte ratio (NLR) has recently been reported as a predictor of Hepatocellular
carcinoma (HCC). However, its prognostic value in HCC still remains controversial. In this study, we aimed to
evaluate the association between NLR and clinical outcome of HCC patients by performing meta-analysis.
Methods: A comprehensive literature search for relevant studies published up to August 2013 was performed by
using PubMed, Ovid, the Cochrane Library and Web of Science databases. Meta-analysis was performed using
hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (95% CIs) as effect measures.
Results: A total of 15 studies encompassing 3094 patients were included in this meta-analysis. Our pooled results
showed that high NLR was associated with poor overall survival (OS) and disease free survival (DFS) in HCC initially
treated by liver transplantation (HR = 3.42, 95% CI:2.41-4.85,P = 0.000; HR = 5.90, 95% CI:3.99-8.70,P = 0.000, respectively)
and surgical resection (HR = 3.33, 95% CI:2.23-4.98, P = 0.000; HR = 2.10, 95% CI: 2.06–2.14, respectively). High NLR was
also associated with poor OS in HCC treated by radiofrequency-ablation (HR = 1.28, 95%CI: 1.10-1.48, P = 0.000), TACE
(HR = 2.52, 95% CI: 1.64-3.86, P = 0.000) and mixed treatment (HR = 1.85, 95% CI: 1.40-2.44, P = 0.000), respectively. In
addition, high NLR was significantly correlated with the presence of vascular invasion (OR = 2.69, 95% CI: 2.01–3.59,
P = 0.000), tumor multifocality (OR = 1.74, 95% CI: 1.30–2.34, P = 0.000) and higher incidence of AFP ≥ 400 ng/ml
(OR = 1.46, 95% CI: 1.01–2.09, P = 0.04).
Conclusion: Elevated NLR indicates a poor prognosis for patients with HCC. NLR may be a convenient,
easily-obtained, low cost and reliable biomarker with prognostic potential for HCC.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignant tumors worldwide with increasing inci-
dence rate over the last several decades across the
world. Meanwhile, its third cancer-related mortality
among varieties of cancers indicates the poor prognosis
of HCC [1]. Despite a significant improvement of HCC
management, including liver transplantation(LT), surgi-
cal resection, radiofrequency ablation(RFA), transarterial
chemoembolization(TACE) and molecular therapy has
been achieved, the long-term outcome is still disappoint-
ing owing to high recurrence and high fatality of the
disease [2]. Thus, there is an urgent need for us to identify
better prognostic biomarkers, especially serum biomarkers* Correspondence: lisq@medmail.com.cn
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unless otherwise stated.for prognosis and metastatic recurrence of HCC, which
would help clinicians to adopt preventive and therapeutic
strategies for risk patients.
In recent years, accumulating evidence demonstrated
that increased systemic inflammation is associated with
poor cancer-specific survival in a variety of cancers [3-7].
These studies revealed that the host’s inflammatory re-
sponse to cancer and/or the systemic effects exerted by
the cancer cells leads to upregulation of the inflammatory
process, inducing the proliferation and metastasis of can-
cer cells by inhibiting apoptosis, promoting angiogenesis,
and repairing DNA damage [8,9]. The presence of a sys-
temic inflammatory response can be detected by both the
elevation of the C-reactive protein (CRP) level [10] and
neutrophil-lymphocyte ratio (NLR) [11].
A high preoperative serum CRP level has been found
to be associated with early recurrence of HCC andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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not routinely measured in many hospitals and CRP level
displays nonspecific change after treatment [13]. Several
studies have shown that an elevation in NLR correlated
with tumor progression, metastasis, and clinical outcome
in a variety of tumors besides HCC [14-18]. Neverthe-
less, conflicting data have emerged regarding the ability
of NLR to predict disease progression and overall sur-
vival (OS) in HCC. Therefore, it is necessary to perform
a meta-analysis to systematically and comprehensively
understand the prognostic value of NLR in HCC.
In this study, we aimed to assess the prognostic signifi-
cance of high NLR for overall survival (OS) and disease-
free survival (DFS) for HCC by pooling outcomes from
the available data. In addition, the correlation between
NLR and patients’ clinicopathological features was also
examined.
Methods
Identification and selection of studies
Study objectives
The primary endpoint was to evaluate patients’ OS and
DFS based on their NLR profiles. The secondary endpoint
was to assess the relation between NLR and patients’ clini-
copathological features (such as vascular invasion).
Search strategy
The following databases were systematically searched in
August 2013 without time restrictions: PubMed, Ovid,
the Cochrane Library and Web of Science databases.
The search strategy was based on combinations of the
following terms: (NLR or neutrophil-lymphocyte ratio)
AND (HCC or hepatocellular carcinoma). Reports in
English were eligible for inclusion. The reference list was
also checked for relevant articles. Investigators were
contacted and asked to supply additional data when key
information relevant to the meta-analysis was missing.
Inclusion criteria of studies
All studies included in this meta-analysis must meet the
following criteria: (1) NLR was measured by serum-
based methods; (2) The relationship between NLR and
OS and/or DFS of patients with HCC was evaluated; (3)
Sample size was greater than 20.
Definitions and data extraction
NLR was defined as the serum absolute neutrophil count
divided by the serum absolute lymphocyte count in periph-
eral blood [19]. OS was defined as the interval between the
medical treatment including liver resection, liver transplant-
ation or radiofrequency ablation (RFA), etc. and the death
or the last observation of patients. DFS was measured
from the date of curative treatment until the detection of
tumor recurrence. Tumor vascular invasion was definedas presence of either macro- or microscopic vascular
invasion (including portal vein invasion, hepatic vein
invasion.). Tumor multifocality was defined as tumor
number greater than 2 or 3. The histologic grade of tumor
was assigned according to the Edmondson Steiner grading
system, studies were grouped as well/moderate (I/II) or
poor (III/IV) degrees of differentiation. All data extractions
were performed separately by X.W.K. and C.D. Disagree-
ments were resolved by discussion.
Qualitative assessment
The quality assessment of included studies was evaluated
by the modified Newcastle–Ottawa quality assessment
scale for cohort studies [20,21] (see “Newcastle-Ottawa
quality assessment scale” section). This scale consists of
three factors: patient selection, comparability of the
study groups, and assessment of outcomes. A score of 0-
9 (labeled as stars) was used to indicate the quality of
each study. Studies labeled with six or more stars were
considered to be of high quality.
Newcastle-Ottawa quality assessment scale
Selection
(1) Representativeness of the exposed cohort
(a) Truly representative of the average HCC patients
in the community*
(b) Somewhat representative of the average HCC
patients in the community*
(c) Selected group of users (e.g., nurses, volunteers)
(d) No description of the derivation of the cohort
(2) Selection of the non exposed cohort
(a) Drawn from the same community as the exposed
cohort*
(b) Drawn from a different source
(c) No description of the derivation of the non
exposed cohort
(3) Ascertainment of exposure (Proof of HCC and
NLR measurement)
(a) Secure record (e.g., surgical records)*
(b) Structured interview*
(c) Written self report
(d) No description
(4) Demonstration that outcome of interest was not
present at start of study
(a) Yes*
(b) No
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(1) Comparability of cohorts on the basis of the
design or analysis
(a) Study controls for recurrence or metastasis*
(b) Study controls for any additional factor (Age,
gender, grade, alpha-fetoprotein level, etc.)*
Outcome
(1) Assessment of outcome




(2) Was follow-up long enough for outcomes to
occur? (Death or recurrence)
(a) Yes (3 years)*
(b) No
(3) Adequacy of follow up of cohorts
(a) Complete follow up – all subjects accounted for*
(b) Subjects lost to follow up unlikely to introduce
bias – small number lost – (25%) follow up, or
description provided of those lost)*
(c) Follow up rate (<75%) and no description of
those lost
(d) No statement
A study can be awarded a maximum of one star (*) for
each numbered item within the Selection and Outcome
categories. A maximum of two stars can be given for
Comparability. Underlined and quoted phrases are pro-
vided in the scale to allow for adjustment to particular
studies. Italicised phrases indicate our interpretation of
the question relevant to this study.
Quantitative analysis (meta-analysis)
Statistical methods
Included studies were divided into two groups for ana-
lysis: those with OS data and those with DFS. Data on
the prognostic ability of NLR for OS and DFS were
pooled across studies. For the quantitative aggregation
of the survival results, hazard ratios (HRs) and their as-
sociated standard errors (SEs) were pooled to give the
effective value. When these statistical variables were not
directly provided in the original articles, they were calcu-
lated from available numerical data using methods re-
ported by Parmar et al. [22]. For the pooled analysis of
the relation between NLR and clinicopathological fea-
tures (such as vascular invasion), odds ratios (ORs) andtheir 95% confidence intervals (95% CIs) were pooled to
give the effective value.
In this study, the cut-off value for high or low NLR
was determined by investigators of each study. A uni-
form NLR was not obtained in this study. A HR >1 im-
plies a worse prognosis in the group with high NLR;
while an OR > 1 indicated higher probability for high
tumor grade, later tumor stage or the presence of vascu-
lar invasion in the group with High NLR. The point esti-
mate of the HR or OR was considered statistically
significant at the p < 0.05 level if the 95% CI for the over-
all HR did not overlap one. In the course of data pool-
ing, we used the I-squared (I2) statistic to measure the
extent of inconsistency among the results and tested the
heterogeneity using chi-square (χ2) test. Because this test
has poor power in the case of few studies, we considered
both the presence of significant heterogeneity at the 10%
level of significance and values of I2 exceeding 56% as an
indicator of significant heterogeneity [23]. The random-
effects model was used if there was heterogeneity be-
tween studies; otherwise, the fixed-effects model was
used. Analysis on main results was performed by using
Review Manager Version 5.0 software (Copenhagen: The
Nordic Cochrane Centre; The Cochrane Collaboration,
2008).
Results
Selection and characteristics of studies
88 records were identified regarding the association of
NLR and HCC via the initial literature search. 72 studies
were excluded after screening the titles or abstracts as
they were either review articles, abstracts, experiment
research, duplicate reports, reports in language other
than English or studies irrelevant to the current analysis.
After careful evaluation by applying our inclusion cri-
teria, a total of 16 eligible studies were identified
[24-39]. Of the 16 studies, two were reported by the
same study center [28,30], and the patients were overlap-
ping or partly overlapping in the studies. To avoid dupli-
cate counting, only one study with more complete data
was selected [30]. Therefore, 15 studies [24-27,29-39] with
3094 patients which met our inclusion criteria were se-
lected for our meta-analysis finally. Three studies were
performed in USA [27,29,38], Japan [24,30,31], China
[25,34,37], and UK [32,33,39] , respectively, one in Taiwan
[35], Korea [26] and in Italy [36], respectively. Liver trans-
plantation as initial treatment for HCC was reported in 5
studies [27,30,34,36,37]. Mixed treatment (including locor-
egional, systemic treatments or supportive care) [26,31,32]
and TACE [29,33,37] were reported in 3 studies, respect-
ively. Surgical resection [24,39] and radiofrequency abla-
tion [25,35] were reported in 2 studies, respectively.
Sample sizes ranged from 54 to 958. Mean or median age
ranged from 48.4 to 72 years. The number of male
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patients with vascular invasion ranged from 25 to 124. OS
was reported or estimated in all studies, whereas DFS was
only provided in nine studies [24,25,27,30,34-36,38,39].
The scores of study quality assessed by Newcastle-Ottawa
quality assessment scale ranged from 5 to 8 (with a mean
of 6.73). A high value indicated better methodology.
HRs were recorded for each study using available data
or the methods described above. Individual study reported
a “high” NLR with survival data, the NLR cut-off value
was determined using different methods in each study.
The basic features of the fifteen studies were summarized
in Table 1.NLR and OS in HCC
All the fifteen studies reported the relationship between
NLR and OS in HCC. Five studies [27,30,34,36,38] pre-
sented the information of NLR correlated with OS in
HCC initially treated by liver transplantation. Pooled
data from these five studies showed that increased
NLR were significantly correlated with poor OS with a
pooled estimate HR of 3.42 (95% CI: 2.41–4.85, P = 0.000;
Figure 1A), and without significant heterogeneity in
the data (χ2 =4.19, I2 = 5%, P = 0.38). 3 studies reported
data on mixed treatment and 3 on TACE, respectively.
The pooled data showed that high NLR were signifi-
cantly associated with poor OS of HCC initially treated
by mixed treatment (HR = 1.85; 95%CI: 40-2.44, P = 0.000,
Figure 1B) and TACE (HR: 2.52, 95% CI: 1.64–3.86,
p =0.000; Figure 1C). There was no any heterogeneity
in both treatment groups (χ2 =1.98, I2 = 0%, p =0.37),
(χ2 =1.92, I2 = 0%, p =0.38). Finally, pooled outcomes
show that NLR significantly correlated with OS in HCC
initially treated by surgical resection (HR: 3.33, 95% CI:
2.23–4.98, P =0.000; Figure 1D), and RFA (HR: 1.28,
95% CI: 1.10–1.48, P = 0.001; Figure 1E).NLR and DFS in HCC
Nine studies reported data on NLR and DFS in HCC.
Five studies offered data on NLR and DFS in HCC ini-
tially treated by LT [27,30,34,36,38]. Pooled data showed
a significant correlation of increased NLR with poor
DFS with a pooled HR estimate of 5.90 (95% CI: 3.99–
8.70, P = 0.000; Figure 2A), and without any heterogen-
eity in the data (χ2 =1.73, I2 =0.0%, p = 0.78). Further-
more, pooled outcomes showed that NLR significantly
correlated with DFS in HCC initially treated by surgical
resection (HR: 2.10, 95% CI: 2.06–2.14, p =0.000;
Figure 2B) without any heterogeneity (X2 =0.30, I2 = 0%,
p =0.58). Finally, 2 studies provided data on radiofre-
quency ablation. But no correlation was observed be-
tween NLR and DFS (HR: 1.07, 95% CI: 0.82–1.40,
p =0.60; Figure 2C).NLR and tumor pathologic features
Eight studies reported the relationship between NLR
and vascular invasion in HCC. High NLR tended to be
correlated with the presence of vascular invasion in all
studies, and a statistical significance was observed in
three studies. Pooled data from all these eight studies
showed a significant correlation between high NLR and
the presence of vascular invasion (OR: 2.69, 95% CI:
2.01–3.59, P = 0.000; Figure 3A).
Six studies reported the correlation between NLR and
tumor multifocality in HCC. High NLR tended to be
correlated with multiple tumors in all studies, and a stat-
istical significance was observed in one study. Pooled
data from all six studies showed a significant correlation
between high NLR and the presence of multiple tumors
(OR: 1.74, 95% CI: 1.30–2.34, P = 0.000; Figure 3B).
Five studies reported the correlation between NLR and
serum AFP level. High NLR tended to be correlated with
higher incidence of AFP ≥ 400 ng/ml in four studies, and
a statistical significance was observed in one study.
Pooled data from all five studies showed a significant
correlation between high NLR and higher incidence of
AFP ≥ 400 ng/ml (OR: 1.46, 95% CI: 1.01–2.09, P = 0.04;
Figure 3C).
Five studies reported the relationship between NLR and
tumor size in HCC. High NLR tended to be correlated with
the presence of large tumor (>3 cm) in three studies, and a
statistical significance was observed in one study. Pooled
data from all five studies showed that high NLR tended to
be correlated with higher incidence of tumor size >3 cm
(OR: 1.35, 95% CI: 0.92–1.98, P = 0.13; Figure 3D).
Three studies reported the relationship between NLR
and tumor grade in HCC. High NLR tended to be corre-
lated with poor tumor grade in two studies. Pooled data
from all three studies showed that high NLR tended to
be correlated with poor tumor grade (OR: 1.32, 95% CI:
0.69–2.52, P = 0.40; Figure 3E).
Correlation between NLR cutoff value and OS in HCC
We compared the prognostic function of NLRs by using
NLR cut-off values of 1.9, 3>NLR ≥ 2, 4>NLR ≥ 3, 4 and 5
reported in the included studies. The results indicated that
all NLRs, except 3>NLR ≥ 2, were statistically correlated
with poor OS of HCC (Table 2). Of these, an NLR of 5
was the most common use, with a pooled HR estimate of
2.87 (95% CI: 2.13–3.84, P = 0.000) from seven studies.
Publication bias
Publication bias estimate was mainly used to evaluate
the reliability of meta-analysis results, especially which
showed statistical significance [40]. Assessment of publica-
tion bias by using Egger’s test [41] (statistical significance
was set at p <0.05) indicated that there were not signifi-
cant publication bias in these studies.
Table 1 Baseline characteristics of the studies in the meta-analysis








Halazun [38] 2009 USA LT 150(119) 57.1 45 5
Motomura [30] 2013 Japan LT 158(92) 57 59 4
Bertuzzo [36] 2011 Italy LT 219(186) 57 124 5
Limaye [27] 2013 USA LT 160(130) 55.5/55.1 25 5
Wang [34] 2011 China LT 101(92) 48.4 30 3
Gomez [39] 2008 UK SR 96(72) 65 49 5
Mano [24] 2013 Japan SR 958(689) 67 NA 2.81
McNally [29] 2013 USA TACE 103(77) 56 NA 5
Huang [37] 2011 China TACE 145(134) 49 39 3.3
Pinato1 [33] 2012 UK TACE 54(40) 63 NA 5
Chen [35] 2011 Taiwan RF 192(95) 65.7 NA 2.4
Dan [25] 2013 China RF 178(159) 57 NA 1.9
Oh [26] 2013 Korea Mix 318((240) 58 107 2.3
Pinato2 [32] 2012 UK Mix 112(90) 65 NA 5













Halazun [38] Pre-LT 37.2 DFS/ OS yes 13 8/9
Motomura [30] Pre-LT 40.3 DFS/OS yes 26 8/9
Bertuzzo [36] Pre-LT 40 DFS/ OS yes 23 5/9
Limaye [27] Pre-LT 38 DFS/ OS yes 28 8/9
Wang [34] Pre-LT 34.2 DFS/ OS yes 33 7/9
Gomez [39] Pre-SR 30 DFS/ OS yes 26 6/9
Mano [24] Pre-SR NA DFS/ OS yes 238 5/9
McNally [29] Pre-TACE 11.1 OS no 18 7/9
Huang [37] Pre- TACE 10 OS yes 59 8/9
Pinato1 [33] Pre-TACE NA OS Yes 9 5/9
Chen [35] Pre-RFA 34 OS/DFS yes 81 7/9
Dan [25] Pre-RFA 52.7 OS/DFS yes 91 7/9
Oh [26] Pre-treatment 13.9 OS yes 189 7/9
Pinato2 [32] Pre-treatment 10 OS yes 25 7/9
Kinoshita [31] Pre-treatment 18 0S no 15 6/9
M, male; F, female; NA, not available.
Treatment describes whether the patients received surgical resection (SR), or liver transplantation (LT) of HCC, transarterial chemoembolization (TACE),
radiofrequency ablation(RFA), mixed treatment (Mix) including locoregional ,systemic treatments or supportive care.
Tumor vascular invasion was defined as presence of either macro- or microscopic vascular invasion (including portal vein invasion, etc.).
OS, overall survival; DFS, disease-free survival.
Study quality is listed using the results of the Newcastle –Ottawa questionnaire.
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NLR was often used to be a traditional inflammation
marker, while its prognostic role in HCC was revealed
just during the recent years. In this meta-analysis study,
we mainly investigated the association between a high
NLR and OS as well as DFS in HCC patients. The pooled
outcomes in these cohorts demonstrated that high NLR
significantly predicted poor OS of HCC patients initiallytreated either by curative therapies including liver
transplantation, surgical resection and RFA or palliative
treatments including TACE and mixed treatment. Fur-
thermore, high NLR also significantly correlated with
shortened DFS of patient treated by liver transplantation
or surgical resection.
We also conducted pooled analysis on the correlation
between high NLR and the pathologic features of HCC.
Figure 1 Meta-analysis of the association between NLR and OS of HCC initially treated by liver transplantation (1A), mixed treatment
(1B), TACE(1C), surgical resection(1D) and RFA(1E). Results are presented as individual and pooled hazard ratio (HR), and 95% confidence
interval (CI).
Xiao et al. BMC Cancer 2014, 14:117 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/117
Figure 2 Meta-analysis of the association between NLR and DFS of HCC initially treated by liver transplantation (2A), surgical resection
(2B) and radiofrequency ablation (2C). Results are presented as individual and pooled hazard ratio (HR), and 95% confidence interval (CI).
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correlated with the presence of vascular invasion, mul-
tiple tumors (satellite nodule) and high level of serum
AFP (400 ≥ ng/ml). All of these 3 factors, especially vas-
cular invasion and multiple tumors, have been docu-
mented to be the most powerful variables associated
with HCC recurrence and compromise long-term sur-
vival [42]. Herein, high NLR is closely associated with
more aggressive phenotype of HCC which is contributed
to lower OS and DFS.
Although the results of the analysis are positive, the
exact explanation for the observation that an elevated
NLR among patients indicates an aggressive phenotype
of tumor is not clearly defined. NLR is an inflammation
marker. Most of the HCCs are related to chronic HBV
or HCV infection, and the host would produce persist-
ent chronic inflammation (hepatitis).The systemic and
local inflammatory response to virus or tumor may pro-
vide a favorable microenvironment for tumor invasion
and metastasis [43]. In addition, a high NLR was associated
with a high infiltration of tumor-associated macrophages
(TAMs), TAMs promote systemic neutrophilia via secret-
ing cytokines such as IL-6 and IL-8 [24]. Furthermore,high expressions of granulocyte colony-stimulating factor
in tumor tissue and macrophage colony-stimulating
factor in peritumoral tissue are also associated with el-
evated circulating neutrophils [44-46]. Neutrophils are
recognized as being the primary source of circulating
vascular endothelial growth factor (VEGF), which has
been established as a major contributor to tumor related
angiogenesis, and hence increased the propensity of can-
cers metastasis [47]. On the other hand, tumor cells can
reduce cytotoxic T lymphocyte (CTL) infiltration in the
tumor by producing immunosuppressive cytokines such
as vascular endothelial growth factor (VEGF), transform-
ing growth factor–β (TGF-β), IL-10 and by consuming IL-
2, a cytokine that is critical for maintaining CTL function
[48]. Thus, NLR reflects an immune microenvironment
that favors tumor vascular invasion and suppresses the
host immune surveillance.
Our results should be interpreted cautiously since
some limitations exist in this present meta-analysis.
First, the cutoff value for defining high NLR has not
been unified (2, 3, 4 or 5) in these studies, which leaded
to between-study heterogeneity. Furthermore, different
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Favours Normal NLR Favours Elevated NLR
Figure 3 Meta-analysis of the association between NLR and vascular invasion (3A), tumor multifocality (3B), incidence of AFP≧400
ng/ml (3C), tumor >3 cm (3D) and poor tumor grade (3E) in HCC. Results are presented as individual and pooled odds ratio (OR), and 95%
confidence interval (CI).
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HR 95%CI p Heterogeneity
X2 I2 P*
NLR = 5 7 2.87 2.14–3.84 0.000 6.04 1% 0.42
NLR = 4 1 5.10 1.81–14.12 0.002 NA NA NA
4>NLR ≥ 3 2 2.32 1.58–3.42 0.000 0.29 0% 0.59
3>NLR ≥ 2 3 1.96 0.82–4.67 0.13 347.73 99% 0.000
NLR = 1.9 1 1.58 1.03–2.44 0.04 NA NA NA
NLR: neutrophil-lymphocyte ratio; HR: hazard ratio; CI: confidence interval; NA:
not available. “4>NLR ≥ 3” means a NLR cutoff value greater than or equal to
3 but less than 4; “3>NLR ≥ 2” means a NLR cutoff value greater than or equal
to 2 but less than 3.
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future large sample study to give a definitive cutoff value
of NLR with good sensitivity and specificity is needed.
Second, there was considerable clinical heterogeneity in
the comparison of OS and DFS regarding different initial
treatment, and thus, a meta-analysis of all included stud-
ies would not be appropriate. Third, these studies mainly
focused on preoperative NLR, and the clinical signifi-
cance of postoperative NLR change, which may dynamic
reflect the change of balance between host inflammatory
response and immune response after treatment, is largely
unclear. Fourth, since our meta-analysis was carried out
on the pooled data, strong recommendations at an indi-
vidual patient level could not be obtained.
Conclusions
In summary, the present meta-analysis provides coherent
evidence that the elevated NLR is of strong prognostic sig-
nificance in patients with HCC treated either by curative
or palliative methods. Compared to other prognostic
markers, NLR seems to be a convenient, easily-obtained
and repeated, low cost and reliable predictor for HCC pa-
tients. A definitive cutoff value of NLR based on future
large sample study is recommended. HCC patient with
high NLR may benefit from anti-inflammatory treatment.
Future research to test this hypothesis is necessary.
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